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Capsule Summary: Differential expression of chemokine receptors on lymphocytes 24 
enables tissue and disease specific recruitment and activation of various lymphocytes. 25 
We have shown that human ILC2s display a different subset of functional chemokine 26 
receptors when isolated from blood or lung tissue.  27 
 28 
Key Words: ILC2; chemokine receptor; T-cells. 29 
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  30 
Abbreviations 31 
ILC2: group 2 innate lymphoid cell 32 
LTi: lymphoid tissue inducer cell 33 
NK cell: natural killer cell 34 
Th-cell: T-helper cell 35 
PBMCs: Peripheral blood mononuclear cells 36 
MFI: mean fluorescence intensity 37 
CCR: chemokine receptor (CC motif) 38 
CXCR: chemokine receptor (CXC motif) 39 
 40 
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Main text: words 42 
To The Editor, 43 
Innate lymphoid cells (ILCs), primarily found at mucosal barriers, provide immediate 44 
protection against the establishment and spread of infection. ILCs have been divided into 45 
three subsets analogous to helper T (Th) cells (1); ILC1, ILC2 and ILC3, ILC2s are similar to 46 
Th2 cells and express IL-4, IL-5 and IL-13 and were initially identified as a non-T, non-B cell 47 
source of type 2 cytokines (2). They are found in the blood, gut, skin and lung where they 48 
contribute to host defence. Upon activation, ILCs rapidly produce a large quantity of 49 
cytokines and other mediators, which attract and activate other inflammatory cells. In various 50 
models of airway disease ILC2 numbers have been shown to increase with allergen challenge 51 
leading to a significant increase in type 2 inflammatory cytokines (3). Recent studies have 52 
demonstrated the existence of a complex interplay between lung epithelial cells and ILC2s 53 
that is required for asthma persistence in a mouse model. Furthermore, human studies have 54 
suggested that ILC2s provide the key link between viral infection and airway inflammation 55 
leading to asthma exacerbations (4).  56 
ILC2s are produced from precursor cells in the bone marrow and ILC precursors have been 57 
identified in human blood, however there is debate about how ILCs populate the adult tissue 58 
with some studies indicating that they are predominantly tissue resident cells (5). An 59 
important question in ILC biology is to understand the mechanisms by which both progenitor 60 
and mature cells are recruited to the peripheral tissues such as the lung.  61 
A significant class of cell surface receptors known to be important for immune cell migration 62 
are the chemokine receptors (6). Importantly, upregulation of key chemokines has been 63 
observed in the bronchial biopsies of asthmatic patients following allergen challenge. Due to 64 
this there has been much interest in the possibility of developing antagonists, which inhibit 65 
receptor activation, to prevent unwanted cells from being recruited to sites of inflammation 66 
such as the lung during asthma exacerbation (7). Using flow cytometry we assessed the 67 
expression of chemokine receptors on T-cells and ILC2s in both human blood and lung 68 
samples. For full methods please see online supplement. The mean data are represented in 69 
Figure 1. (11 blood donors and 5 lung samples). The pattern of receptor expression broadly 70 
agreed with previous reports for CD3+ T-cells. A smaller subset of receptors tested were 71 
readily detectable on ILC2s. These data were reflected at the RNA level as confirmed using 72 
real-time PCR probes to detect the different chemokine receptors in cDNA synthesised from 73 
RNA isolated from fresh ILC2 and T-cells (Supplemental Figure 4). 74 
Although highly detectable on blood derived T-cells, CCR7 was not detected on ILC2s 75 
isolated from the blood or lung. CCR7 expression has previously been described on 76 
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lymphocyte precursors within the bone marrow but is only maintained on mature ILC1 and 77 
ILC3s, in particular subsets of ILCs found in the spleen and lymph nodes (8). Our data 78 
suggests that CCR7 does not play a role in the trafficking of mature ILC2s in the blood or 79 
lung tissues. CXCR5 and CXCR6 were only expressed on a small subset of blood T-cells and 80 
even fewer (<5%) lung T-cells. Furthermore, <5% of ILC2s displayed CXCR5 or CXCR6 81 
receptor in either compartment. These results are consistent with the notion that CXCR5 is 82 
largely involved in B-cell homing and that CXCR6 is important for the retention of T-cells in 83 
the liver, and for the emigration of ILC3s from the bone marrow to the small intestine (8). 84 
CCR9, thought to direct cells to the small intestine was only detectable on around 10% of 85 
ILC2s in lung tissue.  86 
Several receptors were significantly (p <0.05) upregulated in lung tissue derived ILC2s 87 
compared to the cells isolated from the blood including CCR3 and CXCR4 (Figure 4). CCR3 88 
in combination with CCR4 has been shown in multiple T-cell studies (7) to regulate 89 
recruitment to the lung. Furthermore, the potent inflammatory ligand (CXCL12) acting via 90 
CXCR4 appears to coordinate with CCL11 activation of CCR3 and CCL22 stimulation of 91 
CCR4 to recruit lymphocytes to the lung and generate an inflammatory reaction (7). Our data 92 
indicate that a similar mechanism could be used to activate or recruit ILC2s to the airways 93 
thereby driving inflammation.  94 
The receptors displayed on the highest proportion of ILC2s isolated from both blood and lung 95 
tissues were CCR2, CCR4, CCR5 and CCR6. We therefore wished to determine if these 96 
receptors could be used to activate blood ILC2s via various chemokine ligands. Since ILC2s 97 
are only found as a low percentage of human PBMCs traditional chemotaxis assays would 98 
have been difficult to reliably perform. We therefore used an actin polymerization assay as a 99 
marker of receptor activation. The ligands chosen for this assay (Supplemental table 2) have 100 
all been detected in the lung (7) and were based on their receptor specificity. The stimulation 101 
time was optimized to give the largest signal window (Supplemental Figure 5). Both ILC2s 102 
and T-cells displayed ligand-dependent increases in their F-actin content following 10sec 103 
stimulation with the chemokines (Figure 2). Due to the short duration of the assay it is 104 
unlikely that these effects are through indirect activation of other immune cells. The potency 105 
for each ligand was similar between the T-cells and ILC2s however, the maximal responses 106 
were significantly (p <0.05) different for all but CCL2 stimulation of CCR2, perhaps 107 
indicating differences in the number of the receptors expressed on each cell type. Comparing 108 
the response of ILC2s to each ligand (Figure 2E and Supplemental table 2) reveals that the 109 
strongest response is seen via CCR4, with CCR5 and CCR6 showing similar lower levels of 110 
activation and CCR2 an intermediary response. These values may reflect differences in 111 
receptor number on the ILC2 cell surface and may correspond to their roles in cell activity 112 
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and tissue recruitment as it is thought that a higher receptor number is required to achieve cell 113 
chemotaxis than. In T-cells CCR5 does not direct tissue specific recruitment but is required in 114 
combination with different panels of receptors to enable migration (7). Therefore it may be 115 
that initial activation of ILC2s by the more highly expressed receptors occurs before 116 
chemotaxis is enhanced through the binding of CCR5 specific ligands  117 
Given that a higher proportions of “activated” IL-5+, IL-13+ ILC2s have been shown to 118 
correlate with asthma severity (9) and that mouse models of asthma demonstrate that an 119 
increase in ILC2 number is sufficient for airway hyper responsiveness, targeting the 120 
activation and recruitment of these cells is an attractive treatment strategy. Our data provide 121 
new insight into the potential mechanisms by which ILC2s may be recruited or activated in 122 
the human blood and lung, and may therefore allow rational selection of future therapeutics 123 
targeting ILC2s in airway disease. 124 
C Weston PhDa,  125 
BMJ Rana PhDb,c,  126 
DJ Cousins PhDa,b  127 
From  128 
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Figure Legends 177 
 178 
Figure 1: ILC2s and T-cells isolated from human lung display different 179 
chemokine receptors to those derived from blood. A) Percentage of CD3+ T-cells 180 
from blood (white) and lung tissue (grey) expressing the indicated chemokine 181 
receptors. B) Percentage of ILC2s from blood (white) and lung (red) expressing the 182 
indicated chemokine receptors. Data is mean ± standard error of the mean (SEM) of 183 
11 (PBMC) and 5 (lung) independent donors.  184 
 185 
Figure 2: ILC2s respond to various chemokine receptor ligands in a dose 186 
dependent manner. Activation of A) CCR2, B), CCR4, C) CCR5, D) CCR6 187 
receptors on ILC2s and T-cells was determined following 10s stimulation with a 188 
range of concentrations of the indicated ligands. E) Normalised ILC2 response for 189 
each receptor/ligand combination. All data is mean ± SEM from 5 independent 190 
experiments. 191 
 192 
 193 
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Supplemental Methods 
 
PBMC isolation. Peripheral blood mononuclear cells (PBMCs) were obtained from whole 
blood samples taken from healthy, non atopic subjects with no evidence of parasitosis 
recruited at University Hospitals of Leicester NHS Trust, Leicester, UK who had provided 
informed written consent, under ethics (REC reference number 08/H0406/189) approved by 
the Leicestershire, Northamptonshire and Rutland ethics committee. The heparinised blood 
was mixed with an equal volume of PBS and centrifuged (800g, 20min, 22oC) over 
Lymphoprep (Stem Cell Technologies, Cambridge UK). Isolated PBMCs were washed in 
PBS containing 2% FBS (Thermofisher, Paisley, UK) before counting using a 
haemocytometer and trypan blue stain to enable resuspension at the concentration required for 
further experiments as described below. 
 
Isolation of cells from lung tissue. Lung cells were isolated from healthy lung resection 
material taken from patients who had provided informed written consent and were undergoing 
lung surgery. This material was ethically obtained at University Hospitals of Leicester NHS 
Trust, under the auspices of the Midlands lung tissue consortium (REC reference number 
07/MRE08/42). Lung tissue bathed in DMEM containing 2% FBS was enzymatically 
digested for 75 mins at 37oC using hyaluronidase (0.75mg/ml, H3506, Sigma, UK) and 
collagenase (0.75mg/ml, C2674, Sigma) within 1h of resection. The digested tissue was 
filtered by sequentially passing through a 100µm then a 50µm gauze, and washed twice with 
DMEM containing 2% FCS (centrifuging at 230g for 8 mins, 4°C). Cell number was 
determined using haemocytometer and Kimura stain before washing in the absence of serum 
and resuspending in PBS at a concentration of 1x107/100µl for flow cytometric analysis as 
described below. 
 
Analysis of cell surface markers by flow cytometry. For each condition tested 100µl (1x107 
cells) of lung tissue cells were first stained for 20mins with Zombie Aqua fixable viability kit 
following the manufacturer’s protocol (Biolegend, London, UK). Following centrifugation 
(200g 10min, 4oC) the stained cells were then resuspended in 100µl brilliant violet staining 
buffer (Beckton Dickinson, Oxford, UK). PBMCs were adjusted to a concentration 
1x106/100µl prior to cell surface staining. Cells were first incubated with Human Trustain 
(Biolegend, London, UK) at room temperature for 15min to block Fc receptors. Monoclonal 
antibodies: FITC conjugated lineage cocktail (α-CD2, α-CD3, α-CD14, α-CD16, α-CD19, α-
CD56, α-CD235a), EF450 conjugated α-CD3 (UCHT1) (both Affymetrix, Cheshire, UK) 
BV605 conjugated CD123 (6H6), AF647 conjugated α-CD294 (BM16), α-CCR2 (CD192; 
K036C2), α-CCR4 (CD194; L291H4), α-CCR5 (CD195; JF418F1), α-CCR6 (CD196; 
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G034E3), α-CCR7 (CD197; G043H7), α-CCR9 (CD199; L053E8), α-CXCR1 (CD181; 
8F1/CXCR1), α -CXCR3 (CD183; G025H7), α -CXCR4 (CD184; 12G5), α -CXCR5 
(CD185; J252D4), α-CXCR6 (CD186; K041E5) all PE/Cy7 conjugated, PE conjugated α-
CCR3 (CD193; 5E8) and α-CCR10 (6588-5) (all Biolegend, London, UK) were then added 
for a further 20min incubation at room temperature. For lung tissue derived cells BV785 
conjugated α-CD45 (HI30, Biolegend) was also added. Cells were then fixed and any red 
blood cells lysed through the addition of a one-step fix and lyse solution for 20min at room 
temperature (Affymetrix) before centrifugation at 300g 10min 4oC and resuspension in PBS 
supplemented with 2% FBS for acquisition on a four laser Attune NxT flow cytometer using 
NxT software v2.2 (Life Technologies). Compensation settings were determined using 
unstained cells and UltraComp eBeadsTM compensation beads (Affymetrix).  Following the 
exclusion of doublets (Supplemental Figure 1A), lymphocytes were selected based on their 
light scatter properties, (Supplemental Figure 1B). From the selected lymphocyte population 
both CD3+ T-cells (Supplemental Figure 1C) and lineage-, CD123-, CD294+ ILC2s were 
identified (Supplemental Figure 1D & E). CD45 was added as an additional positive marker 
for identifying T-cell and ILC2 populations in lung tissue (Supplemental Figure 1G). Due to 
the observed bimodal distribution of expression, the CD3+ and chemokine receptor positive 
population was used to determine the proportion of ILC2s also displaying each chemokine 
receptor (Supplemental Figure 2 and 3, histograms).   
 
Real time PCR. T-cells and ILC2s were sorted from PBMCs prepared as for flow 
cytometric analysis using a FACS ARIAIII (BD) directly into TRIZOL LS (ThermoFisher.) 
RNA was isolated from the purified cell populations using the miRNeasy mini kit (Qiagen), 
followed by DNAse digestion (Thermofisher) and RNeasy minElute cleanup (Qiagen) 
according to the respective manufacturer’s instructions. RNA integrity was assessed using a 
Bioanalyser (Agilent, Edinburgh UK), according to the manufacturer’s instructions. Due to 
low cell number cDNA samples were synthesized and amplified using the Ovation V2 kit 
(NuGEN, Leek, Netherlands) as per the manufacturer’s instructions. Real-time RT-PCR was 
performed using TaqMan Master mix II (Thermofisher) and TaqMan probesets (all FAM-
MGB) listed in Supplemental table 1. The chemokine receptor signals were compared to an 
18S VIC®-MGB rRNA endogenous control (Thermofisher) Cycling conditions were as 
follows: 50oC for 2 mins, 95oC for 10 mins, 95oC for 15s then 60oC for 1 min for 50 cycles 
on a QuantStudio 5 system (Thermofisher). 
 
Measurement of cellular F-actin content following chemokine stimulation.  Isolated 
PBMCs were adjusted to 1x107cells/100μl. The ability of various recombinant chemokines 
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(CCL2, CCL17, CCL3L1, CCL20, all Biotechne) to activate their cognate receptor was then 
tested through measurement of chemokine-induced increases in the filamentous (F)-actin 
content of both CD3+ T-cells and ILC2s. The method has previously been demonstrated as a 
marker for T-cell activation (1-2) Briefly, 100µl of cells per 10-point dose response curve 
were taken, Fc receptors blocked and stained with FITC conjugated CD123 and lineage 
cocktail, AF647 conjugated CD294, EF450 conjugated CD3 and the required PE/cy7 
conjugated chemokine receptor antibodies for 20min at room temperature. Cells were washed 
in PBS containing 2% FBS and then resuspended in pre-warmed (37oC) RPMI 1640 
(ThermoFisher) containing 2% FBS before stimulation for 10sec with the appropriate 
chemokine. The reaction was terminated by the addition of an equal volume of fixation buffer 
from the intracellular fixation and permeabilisation buffer set (Affymetrix) for 30min at room 
temperature. Cells were washed (1200g, 5min) 3 times with 1x permeabilisation buffer (from 
the intracellular fixation and permeabilisation buffer set Affymetrix) and stained with AF555 
conjugated phalloidin (Life Technologies) (30min at room temperature) before washing and 
resuspension in PBS containing 2%FBS. Data was acquired using an Attune NxT cytometer 
running NxT software v2.2. Chemokine-induced changes in F-actin content were quantified 
as an increase in the mean fluorescence intensity (MFI) in the AF555 channel. To account for 
photobleaching and other non-specific effects on AF555 fluorescence the MFI for chemokine 
receptor positive cells was expressed as a fraction of that observed in the population not 
displaying the receptor for each sample. 
 
Data analysis. Analysis of flow cytometry data was performed using FlowJo v10 (Tree star, 
Oregon, USA). Concentration-response curves were fitted using the three-parameter logistic 
equation in Graph Pad PRISM v6 (California, USA) to obtain EC50 values. Statistical analysis 
was performed using a two-way ANOVA and Tukey’s multiple comparison test with a 
probability (p) <0.05 being considered significant.  
 
Supplemental References 
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Supplemental Figure Legends 
 
Supplemental Figure 1: Gating strategy to identify ILC2s and T-cells from human 
peripheral blood (A-E) and Lung (F-K). A) Total PBMCs displayed with singlet gate 
overlaid. B) Lymphocytes (gated cells) selected from single cell population based on light 
scattering properties. C) T-cells identified as the CD3+ population of single cell lymphocytes. 
D) Lineage-, CD294+ cells (boxed region) containing E) the CD123- ILC2s were also selected 
from the single cell lymphocyte population. F) Total cells displayed with singlet gate 
overlaid. G) Lymphocytes (gated cells) selected from single cell population based on light 
scattering properties. H) Live (zombie aqua-), CD45+ cells shown in gated region were 
selected and I) T-cells were identified as the CD3+ population J) Lineage-, CD294+ cells 
(boxed region) containing K) the CD123- ILC2s were also selected from the live, CD45+, 
single cell lymphocyte population. 
 
Supplemental Figure 2: Chemokine receptor expression on T-cells and ILC2s in 
human blood.  Representative flow cytometry data showing the expression of the 
indicated chemokine receptors on CD3+ T-cells (left) and ILC2s (right). Receptor+ 
gate determined using bimodal distribution observed on T-cell populations, numbers 
within gates indicate percentage cells.  
 
Supplemental Figure 3: Expression of chemokine receptors on ILC2s and T-cells 
isolated from lung tissue. A) Representative flow cytometry data showing the 
expression of the indicated chemokine receptors on: CD3+ T-cells (left) and ILC2s 
(right). Receptor+ gate determined using bimodal distribution observed on T-cell 
populations numbers within gates indicate percentage cells.  
 
Supplemental Figure 4: Quantification of chemokine receptor RNA expression in 
T-cells and ILC2s. Relative quantities of the indicated genes were calculated relative 
to 18S mRNA. Plots show mean values (±SEM) for T-cells (black boxes) and ILC2s 
(grey boxes) sorted from PBMCS obtained from 5 independent donors.  
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Supplemental Figure 5:  Chemokines can be used to stimulate human blood cells 
in a time dependent manner. A) CD3+ T-cells and B) Lineage-, CD123-, CD294+ 
ILC2s were identified from within a single cell, lymphocyte gate. C) CCR4 
expression on T-cells (Grey) and ILC2s (Red) with gates used to select positive and 
negative populations overlaid. Phalloidin staining was analysed for D) CCR4- T-cells, 
E) CCR4+ T-cells and F) CCR4+ ILC2s at the indicated time points. Receptor 
response was determined for G) chemokine receptor positive T-cells and H) 
chemokine receptor positive ILC2s at each time point by normalising the phalloidin 
mean fluorescence intensity to that observed on CCR4- cells. (Data shown are mean ± 
SEM of 5 independent donors). 
 
Supplemental table 1: Taqman probes used in this study.  
Gene name Probe Id Gene name Probe Id 
CCR2 Hs00356601_m1 CCR7 Hs01013469_m1 
CCR3 Hs00266213_s1 CCR10 Hs00706455_s1 
CCR4 Hs00356611_s1 CXCR4 Hs00237052_m1 
CCR5 Hs00152917_m1 CXCR5 Hs00540548_s1 
CCR6 Hs01890706_s1 CXCR6 Hs01890898_s1 
  
Supplemental Table 2: Potency (pEC50) and maximal (Emax) responses observed in 
ILC2s and T-cells following 10s stimulation with the indicated receptor: ligand 
combinations. Data are mean ± SEM of experiments from at least 5 independent 
donors.  
 CCR2:CCL2 CCR4:CCL17 CCR5:CCL3L1 CCR6:CCL20 
 
ILC2 T-cell ILC2 T-cell ILC2 T-cell ILC2 T-cell 
pEC50 8.4 
±0.2 8.0 ±0.2 9.6 ±0.2 9.6 ±0.2 8.1 ±0.4 7.7 ±0.2 
8.6 
±0.3* 7.5 ±0.1 
Emax 1.3 
±0.03 
1.2 
±0.02 
1.5 
±0.04*** 
1.2 
±0.02 
1.2 
±0.06** 
1.4 
±0.04 
1.4 
±0.04** 
1.6 
±0.05 
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